Bristol Urological Institute, Southmead Hospital, Bristol, UK.
Curr Opin Urol. 2014 Jan;24(1):3-9. doi: 10.1097/MOU.0000000000000020.
Male patients with lower urinary tract symptoms have historically been managed in a prostate centric fashion. Population studies highlighting the prevalence and significance of storage symptoms, including nocturia, have meant a shift in the way men with lower urinary tract symptoms are assessed and managed. We review the recent guidelines and publications that have addressed this change in approach.
A new β-3 adrenoreceptor agonist has demonstrated significant improvement in storage symptoms and appears to be well tolerated.
We support a continued move towards a patient-focused and management using the current guidelines.
患有下尿路症状的男性患者既往一直采用前列腺为中心的方式进行治疗。强调包括夜尿症在内的储存症状的普遍性和重要性的人群研究，意味着对患有下尿路症状的男性进行评估和管理的方式发生了转变。我们回顾了最近处理这种方法转变的指南和出版物。
一种新型的β-3 肾上腺素能受体激动剂已证明对储存症状有显著改善，且似乎耐受性良好。
我们支持继续朝着以患者为中心的方向发展，并使用当前的指南进行管理。
